Systematic review of levodopa dose equivalency reporting in Parkinson's disease

Movement Disorders - Tập 25 Số 15 - Trang 2649-2653 - 2010
Claire L Tomlinson1, Rebecca Stowe1, Smitaa Patel1, Caroline Rick1, Richard Gray1, Carl E Clarke2,3
1Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
2Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Birmingham, United Kingdom
3School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom

Tóm tắt

Abstract

Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications. © 2010 Movement Disorder Society

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa033447

10.1136/jnnp.37.4.422

10.1002/ana.410400305

10.1002/1531-8257(200003)15:2<230::AID-MDS1005>3.0.CO;2-U

10.1002/mds.10429

10.1007/s10072-009-0101-3

10.1007/s007020050212

10.1002/mds.20750

10.1080/02688690802507775

10.1016/S0140-6736(99)03556-4

10.1056/NEJMoa060281

10.1001/archneur.58.9.1385

10.1212/01.WNL.0000103235.12621.C3

10.1002/mds.20045

10.1016/j.neulet.2009.06.074

10.1093/brain/123.4.733

10.1056/NEJM200006083422304

10.1002/mds.21541

10.1002/mds.21741

10.1212/WNL.52.6.1227

10.1002/mds.20210

Gupta M, 2004, Hallucinations in Parkinson's disease—a study of forty three patients, JAssoc Physicians India, 52, 703

10.1038/nn863

10.1001/jama.287.4.455

10.1111/j.1468-1331.2008.02081.x

10.1007/s00415-004-1605-7

10.1212/01.wnl.0000310812.43352.66

10.1007/s00415-006-0388-4

10.1212/WNL.62.6_suppl_4.S22

10.1007/s00415-006-0426-2

10.1093/brain/121.3.451

10.1136/jnnp.70.4.464

10.1056/NEJM199710093371503

10.1016/j.clineuro.2009.10.008

10.1016/S0140-6736(95)92404-3

10.1016/j.parkreldis.2005.12.008

10.1136/jnnp.2003.032623

10.1007/s00415-005-0784-1

10.1212/WNL.53.1.85

10.1016/j.phrs.2009.03.010

10.1002/mds.22543

10.1001/archneur.1990.00530120030006

10.1002/mds.20920

10.1002/mds.10188

10.3171/jns.2003.99.1.0071

10.1002/mds.10186

10.1002/mds.22694

10.1136/jnnp.2003.022780

Romito LMA, 2003, Bilateral high frequency subthalamic stimulation in Parkinson's disease: long‐term neurological follow‐up, J Neurosurg Sci, 47, 119

10.1056/NEJMoa000827

10.1007/s004150200059

10.1227/01.NEU.0000285347.50028.B9

10.1016/j.surneu.2007.05.058

10.1212/WNL.58.3.396

10.1002/ana.10517

10.1001/jama.2008.929

10.1093/brain/awf084

10.1093/brain/awm111

10.1002/14651858.CD007166.pub2